Price target
55.610.000.00%
The 9 analysts offering 1 year price forecasts for RV7 have a max estimate of — and a min estimate of —.
Analyst rating
Based on 11 analysts giving stock ratings to RV7 in the past 3 months.
EPS
0.00
Reported
Estimate
Reported
Estimate
Surprise
Revenue
0.00
Reported
Estimate
Reported
Estimate
Surprise
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
RV7 EPS for the last quarter is 1.08 CHF despite the estimation of 0.81 CHF. In the next quarter EPS is expected to reach 1.04 CHF. Track more of HALOZYME THERAPEUT financials and stay on top of what is up with the company.
In the next quarter HALOZYME THERAPEUT revenue is expected to reach 259.68 M CHF. Check out HALOZYME THERAPEUT revenue and earnings and make informed decisions.
According to analysts, RV7 price target is 55.61 CHF with a max estimate of 66.79 CHF and a min estimate of 44.53 CHF. Check if this forecast comes true in a year, meanwhile watch HALOZYME THERAPEUT stock price chart and keep track of the current situation with RV7 news and stock market news.
We've gathered opinions of 11 analysts rating RV7 stock in the past 3 months. After counting all points of view, the overall rating was calculated as buy. Note that it's not a trading advice — your own analysis is still required.